No abstract available
Publication types
-
Clinical Trial, Phase III
-
Letter
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adenocarcinoma* / drug therapy
-
Adenocarcinoma* / mortality
-
Adenocarcinoma* / pathology
-
Aged
-
Antibodies, Monoclonal, Humanized* / therapeutic use
-
Antineoplastic Agents, Immunological* / adverse effects
-
Antineoplastic Agents, Immunological* / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols
-
Double-Blind Method
-
Esophagogastric Junction / pathology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Progression-Free Survival
-
Receptor, ErbB-2* / analysis
-
Receptor, ErbB-2* / metabolism
-
Stomach Neoplasms* / drug therapy
-
Stomach Neoplasms* / mortality
-
Stomach Neoplasms* / pathology
-
Trastuzumab / therapeutic use
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
ERBB2 protein, human
-
pembrolizumab
-
Receptor, ErbB-2
-
Trastuzumab